Medicine and Health
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial
A. H. Diacon, C. E. B. Iii, et al.
A groundbreaking phase 2a trial evaluates ganfeborole's early bactericidal activity in treating untreated pulmonary tuberculosis. The study, conducted by a team including Andreas H. Diacon and Clifton E. Barry III, highlights promising results with significant reductions in sputum colony-forming units and demonstrates the drug's potential role in combination therapy.
Playback language: English
Related Publications
Explore these studies to deepen your understanding of the subject.
